Eric L. Michelson
#149,372
Most Influential Person Now
Eric L. Michelson's AcademicInfluence.com Rankings
Eric L. Michelsonmedical Degrees
Medical
#2855
World Rank
#3297
Historical Rank
Cardiology
#276
World Rank
#282
Historical Rank
Eric L. Michelsonphilosophy Degrees
Philosophy
#8196
World Rank
#11529
Historical Rank
Logic
#5223
World Rank
#6606
Historical Rank
Download Badge
Medical Philosophy
Eric L. Michelson's Degrees
- Doctorate Medicine Stanford University
Why Is Eric L. Michelson Influential?
(Suggest an Edit or Addition)Eric L. Michelson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial (2003) (2785)
- Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial (2003) (2428)
- Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme (2003) (1871)
- Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial (2003) (1573)
- Feasibility of treating prehypertension with an angiotensin-receptor blocker. (2006) (894)
- Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. (2007) (887)
- Predictors of mortality and morbidity in patients with chronic heart failure. (2006) (882)
- Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure (2006) (859)
- Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients (2005) (686)
- Recurrent Sustained Ventricular Tachycardia 3. Role of the Electrophysiologic Study in Selection of Antiarrhythmic Regimens (1978) (609)
- Limitations of Routine Long-Term Electrocardiographic Monitoring to Assess Ventricular Ectopic Frequency (1978) (570)
- Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure (2007) (535)
- Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. (2008) (529)
- Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. (2006) (515)
- Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial (2005) (459)
- Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low–Left Ventricular Ejection Fraction Trials (2004) (349)
- Body Mass Index and Prognosis in Patients With Chronic Heart Failure: Insights From the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program (2007) (336)
- Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program (2009) (328)
- Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. (2006) (280)
- Albuminuria in chronic heart failure: prevalence and prognostic importance (2009) (264)
- Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program (2006) (257)
- Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Program (2004) (256)
- Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program (2007) (239)
- Spontaneous Variability of Complex Ventricular Arrhythmias Detected by Long‐term Electrocardiographic Recording (1980) (238)
- The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. (1983) (234)
- Characterization of health‐related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM (2007) (213)
- Instantaneous and Delayed Ventricular Arrhythmias After Reperfusion of Acutely Ischemic Myocardium: Evidence for Multiple Mechanisms (1981) (197)
- Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. (1989) (185)
- Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved (2014) (181)
- Electrophysiologic and anatomic correlates of sustained ventricular tachyarrhythmias in a model of chronic myocardial infarction. (1980) (178)
- Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. (2008) (170)
- Mechanism and prevention of cardiac arrhythmias in chronic hemodialysis patients. (1980) (167)
- Nonsustained ventricular tachycardia in ambulatory patients: characteristics and association with sudden cardiac death. (1980) (164)
- Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. (2007) (160)
- Recurrent Sustained Ventricular Tachycardia: 4. Pleomorphism (1979) (153)
- Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. (2012) (152)
- Detection of delayed ventricular activation on the body surface in dogs. (1981) (152)
- Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity (CHARM) programme (2003) (150)
- Reperfusion ventricular tachyarrhythmias: correlation with antecedent coronary artery occlusion tachyarrhythmias and duration of myocardial ischemia. (1981) (139)
- Aspirin- and coumadin-related bleeding after coronary- artery bypass graft surgery. (1978) (135)
- Cellular electrophysiologic characteristics of chronically infarcted myocardium in dogs susceptible to sustained ventricular tachyarrhythmias. (1983) (135)
- The Limitations of Epicardial Mapping as a Guide to the Surgical Therapy of Ventricular Tachycardia (1978) (131)
- Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. (2011) (131)
- Postoperative arrhythmias after coronary artery and cardiac valvular surgery detected by long-term electrocardiographic monitoring. (1979) (130)
- Sustained ventricular tachycardia: evidence for protected localized reentry. (1978) (129)
- Cardiovascular complaints. Correlation with cardiac arrhythmias on 24-hour electrocardiographic monitoring. (1980) (126)
- Polymorphous ventricular tachycardia associated with normal and long Q-T intervals. (1982) (123)
- Adherence to medication according to sex and age in the CHARM programme (2009) (122)
- Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. (2000) (121)
- The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. (2011) (116)
- The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study. (2002) (113)
- Intramyocardial Conduction: A Major Determinant of R‐wave Amplitude During Acute Myocardial Ischemia (1982) (110)
- Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. (1999) (109)
- Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies. (1983) (107)
- Reduced Space Constant in Slowly Conducting Regions of Chronically Infarcted Canine Myocardium (1983) (99)
- Role of the perinodal region in atrioventricular nodal reentry: evidence in an isolated rabbit heart preparation. (1983) (94)
- Cardiac arrhythmias. Frequency during fiberoptic bronchoscopy and correlation with hypoxemia. (1981) (92)
- Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. (2006) (91)
- Relation of preoperative use of aspirin to increased mediastinal blood loss after coronary artery bypass graft surgery. (1978) (85)
- Initiation of Sustained Ventricular Tachyarrhythmias in a Canine Model of Chronic Myocardial Infarction: Importance of the Site of Stimulation (1981) (85)
- The Hemoglobin A 1 c Level as a Progressive Risk Factor for Cardiovascular Death , Hospitalization for Heart Failure , or Death in Patients With Chronic Heart Failure (2008) (83)
- Failure of Antiarrhythmic Drugs to Prevent Experimental Reperfusion Ventricular Fibrillation (1981) (82)
- Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. (2006) (76)
- Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. (2005) (76)
- Ethmozin: a new antiarrhythmic agent developed in the USSR. Efficacy and tolerance. (1979) (73)
- Retinal arteriolar changes as an indicator of coronary artery disease. (1979) (71)
- Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme (2010) (69)
- Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. (1998) (67)
- Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme (2007) (66)
- Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. (2001) (64)
- Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program (2009) (62)
- Reevaluation of the role of atrial systole to cardiac hemodynamics: evidence for pulmonary venous regurgitation during abnormal atrioventricular sequencing. (1983) (61)
- Thrombolytic therapy of acute myocardial infarction. Keeping the unfulfilled promises. (1992) (60)
- Trial of preventing hypertension: design and 2-year progress report. (2004) (59)
- Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme (2006) (59)
- Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators. (2000) (57)
- R‐wave Amplitude Variations During Acute Experimental Myocardial Ischemia: An Inadequate Index for Changes in Intracardiac Volume (1981) (56)
- Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. (2004) (55)
- Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. (2005) (54)
- The evaluation and management of drug effects on cardiac conduction (PR and QRS intervals) in clinical development. (2013) (54)
- Antihypertensive Efficacy of Candesartan in Comparison to Losartan: The CLAIM Study (2001) (53)
- Repetitive responses to ventricular extrastimuli: incidence, mechanism, and significance. (1980) (50)
- Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. (2008) (50)
- Diastolic “Locking” of the Mitral Valve: The Importance of Atrial Systole and Intraventricular Volume (1983) (49)
- Effects of the site and timing of atrioventricular nodal input on atrioventricular conduction in the isolated perfused rabbit heart. (1984) (48)
- Fascicular conduction disturbances after coronary bypass surgery (1978) (48)
- Echocardiographic features of atrioventricular and ventriculoatrial conduction. (1980) (47)
- Adenosine mediates the negative chronotropic action of adenosine 5'-triphosphate in the canine sinus node. (1987) (45)
- Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group. (1999) (44)
- Bradyarrhythmias: clinical significance and management. (1983) (44)
- The Evaluation of New Antiarrhythmic Drugs (1981) (41)
- The Origin of Ventricular Arrhythmias 24 Hours Following Experimental Anterior Septal Coronary Artery Occlusion (1977) (40)
- Relation of death within 90 days of non-ST-elevation acute coronary syndromes to variability in electrocardiographic morphology. (2009) (40)
- Strength‐Interval Relations in a Chronic Canine Model of Myocardial Infarction: Implications for the Interpretation of Electrophysiologic Studies (1981) (37)
- TROPHY study: Outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertension. (2008) (37)
- Atrioventricular nodal conduction during atrial fibrillation in rabbit heart. (1982) (36)
- Multiclinic comparison of labetalol to metoprolol in treatment of mild to moderate systemic hypertension. (1983) (36)
- Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. (2008) (36)
- Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. (1998) (36)
- The mechanism of AV junctional reentry: Role of the atrio‐nodal junction (1981) (35)
- 1145-122 Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: Results from CHARM (2004) (34)
- Effects of procainamide on strength-interval relations in normal and chronically infarcted canine myocardium. (1981) (33)
- Calcium channel blockers in systemic hypertension. (1986) (33)
- Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium. (2013) (33)
- Recurrent Sustained Ventricular Tachycardia 4 (2005) (32)
- Esmolol: safety and efficacy in postoperative cardiothoracic patients with supraventricular tachyarrhythmias. (1988) (32)
- Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension. (1983) (32)
- Electrophysiologic study of the left ventricle: indications and safety. (1979) (30)
- Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme (2005) (30)
- Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. (2008) (30)
- Vagally induced hyperpolarization in atrioventricular node. (1986) (30)
- Initiation of ventricular tachyarrhythmia with programmed stimulation: sensitivity and specificity in an experimental canine model. (1982) (29)
- Thrombolytic therapy of acute myocardial infarction: emerging challenges of implementation. (1987) (29)
- Effects of adenosine and adenosine 5'-triphosphate on ventricular escape rhythm in the canine heart. (1986) (28)
- Combination propranolol and bepridil therapy in stable angina pectoris. (1985) (28)
- Morphological and electrophysiological correlates of atrioventricular nodal response to increased vagal activity. (1990) (27)
- Differential sensitivity of cardiac pacemakers to exogenous adenosine in vivo. (1990) (26)
- Differential effects of procainamide, lidocaine and acetylstrophanthidin on body surface potentials and epicardial conduction in dogs with chronic myocardial infarction. (1988) (26)
- Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction. (2012) (24)
- Role of early cycle ventricular extrasystoles in initiation of ventricular tachycardia and fibrillation: evaluation of the R on T phenomenon during acute ischemia in a canine model. (1982) (23)
- Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. (2003) (23)
- Inducible sustained ventricular tachycardia 4 years after experimental canine myocardial infarction: electrophysiologic and anatomic comparisons with early healed infarcts. (1988) (23)
- Early recognition of surgically correctable causes of excessive mediastinal bleeding after coronary artery bypass graft surgery. (1980) (23)
- Cardiac Effects of Adenosine and ATP a (1990) (23)
- Nonarrhythmogenicity of therapeutic cryothermic lesions of the myocardium. (1985) (22)
- Multiple cardiac output measurements in man. Evaluation of a new closed-system thermodilution method. (1979) (21)
- Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. (2000) (21)
- Fixed coupling: different mechanisms revealed by exercise-induced changes in cycle length. (1978) (21)
- R-wave amplitude responses to rapid atrial pacing: a marker for myocardial ischemia. (1984) (21)
- Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock. (2019) (20)
- Evidence for vagal involvement in the electrophysiologic actions of exogenous adenosine and adenosine triphosphate in the canine heart. (1985) (19)
- Extracellular potassium ion dynamics and ventricular arrhythmias in the canine heart. (1989) (19)
- Histopathologic factors conducive to experimental ventricular tachycardia. (1985) (18)
- Effect of postganglionic vagal stimulation on the organization of atrioventricular nodal conduction in isolated rabbit heart tissue. (1986) (18)
- Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study Investigators. (1999) (18)
- An Evaluation of the Effects of an Angiotensin Receptor Blocker on Health‐Related Quality of Life in Patients With High‐Normal Blood Pressure (Prehypertension) in the Trial of Preventing Hypertension (TROPHY) (2008) (17)
- Interacting negative chronotropic effects of adenosine and the vagus nerve on the canine sinus node. (1988) (17)
- Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure – Assessment of Reduction in Mortality and morbidity (CHARM) programme (2010) (17)
- Task force 1: Training in clinical cardiology (1995) (16)
- Newer antiarrhythmic drugs. (1988) (15)
- Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study Investigators. (1999) (15)
- Effects of beta-adrenergic blockade on plasma lipids: A double-blind randomized placebo-controlled multi-center comparison of labetalol and metoprolol in patients with hypertension (1982) (14)
- Calcium antagonists in cardiology: Update on sustained‐release drug delivery systems (1991) (12)
- Increased normoxic-to-ischemic tissue borderzone as the cause for reentrant ventricular tachyarrhythmias. (1982) (12)
- Treatment of severe hypertension with labetalol compared with methyldopa and furosemide. Results of a long-term, double-blind, multicenter trial. (1983) (12)
- Importance of the pacing mode in the initiation of ventricular tachyarrhythmia in a canine model of chronic myocardial infarction. (1985) (11)
- Further electrophysiologic and anatomic correlates in a canine model of chronic myocardial infarction susceptible to the initiation of sustained ventricular tachyarrhythmias (1981) (11)
- Extracellular potassium dynamics in the border zone during acute myocardial ischemia in a canine model. (1988) (11)
- Considerations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: A report from the Cardiac Safety Research Consortium. (2015) (11)
- Labetalol: an alpha- and beta-adrenoceptor blocking drug. (1983) (11)
- Limitations of infrequent holter monitoring in assessing antiarrhythmic efficacy (1978) (10)
- Description of Chronic Canine Myocardial Infarction Models Suitable for the Electropharmacologic Evaluation of New Antiarrhythmic Drugs (1981) (10)
- Nicardipine and hydrochlorothiazide in essential hypertension (1989) (10)
- Hemodynamic effects of cardiac pacing. (1983) (9)
- Meobentine sulfate: Antiarrhythmic efficacy and mechanism of action in a chronic canine model of myocardial infarction susceptible to ventricular tachyarrhythmias (1981) (9)
- The Effects of Candesartan Cilexetil in Isolated Systolic Hypertension: A Clinical Experience Trial. (2000) (9)
- Long term efficacy, safety, and tolerability of candesartan cilexetil added to hydrochlorothiazide in patients with severe systemic hypertension (1999) (8)
- What Animal Models Should Be Used to Define Antiarrhythmic Efficacy? Acute Dog Models (1981) (8)
- Phasic effects of postganglionic vagal stimulation on atrioventricular nodal conduction. (1986) (8)
- Confirmation of a new technique for detecting slow ventricular activation on the body surface (1981) (8)
- THE USE OF ANIMAL MODELS IN THE STUDY OF THE ELECTROPHYSIOLOGY OF SUDDEN CORONARY DEATHS * (1982) (8)
- A new mechanism for atrioventricular nodal gap-vagal modulation of conduction. (1989) (8)
- Dilevalol compared with propranolol and placebo for systemic hypertension. (1989) (8)
- Evaluation of electrophysiologic factors modifying results of programmed electrical stimulation in animal preparations of myocardial infarction. (1986) (8)
- Influence of the site of stimulation on atrioventricular nodal refractory periods and the effect of verapamil. (1986) (8)
- Vagal component in the chronotropic and dromotropic actions of adenosine and ATP. (1987) (7)
- Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial (2016) (7)
- Role of the vagus in modulation by Ca2+ of the depressant action of adenosine and adenosine 5'-triphosphate on the canine sinus node in vivo. (1987) (7)
- Diastolic 'locking' of the mitral valve: possible importance of diastolic myocardial properties. (1986) (7)
- Increased R-wave amplitude induced by acute myocardial ischemia in the dog: a predictor of malignant ventricular arrhythmias. (1982) (7)
- Effects of candesartan cilexetil on health-related quality of life in black patients with systemic hypertension in the ABC Trial. (2000) (7)
- Failure of antiarrhythmic drugs to affect epicardial delay during acute experimental coronary artery occlusion and reperfusion: correlation with lack of antiarrhythmic efficacy. (1981) (7)
- Ambulatory monitoring of the cardiac patient. (1988) (6)
- Donor alloreactivity may predict acute graft‐versus‐host disease in HLA‐matched bone marrow transplantation for leukemia in early remission (1992) (6)
- Effects of AV Sequential Versus Asynchronous AV Pacing on Pulmonary Hemodynamics (1986) (6)
- Disturbances of Cardiac Rhythm (1993) (6)
- Ventricular tachyarrhythmia initiation in a canine model of recent myocardial infarction. Comparison of unipolar cathodal, anodal and bipolar stimulation. (1987) (6)
- On the mechanisms of cardiac electrophysiologic actions of adenosine and adenosine 5'-triphosphate. (1988) (6)
- Correlation of the incidence of reperfusion ventricular arrhythmias with the duration of experimental coronary artery ligation (1980) (5)
- Canine models for ventricular tachyarrhythmia. (1981) (5)
- Comparison of the Side-Effect Profile of Dilevalol with Propranolol (1988) (5)
- Long-term efficacy, tolerability, and safety of the combination of enalapril and felodipine ER in the treatment of hypertension (1998) (5)
- Early repolarization: normalization of the electrocardiogram with exercise as a clinically useful diagnostic feature. (1995) (5)
- Evidence Against Prostaglandin Mediation of the Differential Electrophysiologic Effects of ATP Versus Adenosine in the Canine Heart (1986) (5)
- The Second Annual Think Tank on Prevention of Sudden Cardiac Death in the Young: Developing a rational, reliable, and sustainable national health care resource. A report from the Cardiac Safety Research Consortium (2018) (5)
- Canine AV nodal artery: anatomical variations and a detailed description of cannulation technique. (1987) (5)
- Supernormal response and conduction in depressed isolated canine ventricular muscle exposed to high potassium concentration. (1983) (5)
- Differential vagal effects on antegrade vs. retrograde atrioventricular conduction. (1987) (5)
- Corrigendum to ‘Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved’ [Eur J Heart Fail 2014;16:33–40] (2014) (5)
- Recent Advances in Antiarrhythmic Drug Research: Studies in Chronic Canine Myocardial Infarction‐Ventricular Tachyarrhythmia Models (1982) (4)
- Present Status of Clinical Electrophysiologic Studies: Introduction—What Studies Are Necessary (1984) (4)
- The composite cardiac electrogram: Fact or artifact? (1980) (4)
- The challenge of nurse-physician collaborative practices: improved patient care provision and outcomes. (1988) (4)
- Long-term efficacy, tolerability, and safety of the combination of enalapril and felodipine ER in the treatment of hypertension. Enalapril-Felodipine ER Factorial Study Group. (1998) (4)
- The lethal late consequences of small infarcts (1980) (4)
- Guidelines for training in adult cardiovascular medicine. Core Cardiology Training Symposium (COCATS). Task Force 1: training in clinical cardiology. (1995) (4)
- 835-5 Candesartan improves functional class across a broad spectrum of patients with chronic heart failure: Results of the candesartan in heart failure-assessment of reduction in mortality and morbidity programme (CHARM) (2004) (4)
- Surgical therapy for ventricular tachyarrhythmias. (1983) (4)
- Transtelephonic electrocardiographic monitoring for the detection and treatment of cardiac arrhythmias. (1988) (4)
- Evaluation of arrhythmogenicity of surgically induced endocardial versus ischemic myocardial damage. (1984) (4)
- Atrial alternans: experimental echocardiographic and hemodynamic demonstration during programmed pacing. (1981) (4)
- Ventricular Tachycardia Terminated by Carotid Sinus Massage (1979) (4)
- THE INCIDENCE OF ARRHYTHMIAS AND CLINICAL ARRHYTHMIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES TREATED WITH TICAGRELOR OR CLOPIDOGREL IN THE PLATO TRIAL (2010) (4)
- 1069-113 Cause of death across full spectrum of ventricular function in patients with heart failure: The CHARM study (2004) (3)
- Contribution of the Concept of Dual Pathways in the Atrioventricular Node to the Understanding of Supraventricular Tachycardias and Conduction Abnormalities (1983) (3)
- Transtelephonic ECG monitoring in myocardial ischemia and infarction. (1988) (3)
- 531 Incidence and predictors of hyperkalemia in patients with heart failure - an analysis of the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) program (2006) (3)
- Disturbances of Cardiac Rhythm and Conduction in the Elderly (1987) (3)
- Initiation of sustained ventricular tachyarrhythmias in a model of chronic infarction: Importance of the site of stimulation (1980) (3)
- Vagal control of the atrioventricular node--in vitro observations. I. Electrophysiological mechanism underlying the effects of brief vagal discharges on atrioventricular nodal conduction. (1988) (3)
- Interactive negative chronotropic actions of adenosine and verapamil on the canine sinus node in vivo. (1987) (3)
- Histopathologic Correlates of Inducible Ventricular Tachycardia in Two Experimental Canine Models of Myocardial Infarction (1986) (3)
- The Role of Animal Models in Electrophysiologic Studies of Life‐Threatening Arrhythmias (1986) (3)
- Vagal control of the atrioventricular node--in vitro observations. II. Differential postganglionic vagal influence on anterograde atrioventricular nodal conduction and junctional pacemaker activity. (1988) (2)
- The role of the phase relation between the atrial excitatory waves in determining the functional refractory properties of the atrioventricular node. (1984) (2)
- Cellular electrophysiology of a mottled infarct in dogs 4 and 15 days after coronary occlusion and reperfusion (1980) (2)
- 1108-109 Low hemoglobin is an independent predictor of adverse fatal and nonfatal outcomes in both reduced and preserved systolic function chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity program (CHARM) (2004) (2)
- Tachycardia and Apparent Sino‐Atrial Block Due to Concealed Sinus Node Re‐entry (1983) (2)
- Mechanisms of Ventricular arrhythmias: From laboratory to bedside (1995) (2)
- Clinical Pharmacology Education in a Division of Cardiology (1991) (2)
- Role of Pacing in the Treatment of Tachycardias (1984) (2)
- Propensity to develop ventricular tachyarrhythmias: differences in homogeneous versus heterogeneous myocardial infarcts. (1985) (2)
- Fascicular conduction distrubances after coronary bypass surgery. (1978) (2)
- Temporal dispersion of refractoriness: Lack of correlation with antiarrhythmic efficacy in a model of chronic infarction (1980) (2)
- Creation of Experimental Atrioventricular Block using DC Shock via a Percutaneous Transaortic Electrode Catheter (1983) (2)
- A047: Dose response of candesartan cilexetil in essential hypertension: a clinical experience trial (2000) (2)
- A multicenter double-blind study of the efficacy and safety of once and twice daily dilevalol compared to propranolol. (1989) (1)
- Ventricular refractoriness at twice diastolic excitability threshold: An unpredictable source of variability (1980) (1)
- Efficacy and tolerability of the combination of Candesartan cilexetil and hydrochlorothiazide in systemic hypertension (1999) (1)
- Abstract 3594: Lack of Interaction between Angiotensin Receptor Blocker and Aspirin in Patients with Heart Failure (2006) (1)
- Evaluation of the Patient with Palpitations and Non-life-threatening Cardiac Arrhythmias (2001) (1)
- Comparative susceptibility to ventricular tachyarrhythmia initiation in dogs with homogeneous versus heterogeneous chronic myocardial infarctions (1982) (1)
- Adenosine-vagus interaction at the cellular level. (1987) (1)
- Update on cardiac pacemakers: description, complications, indications, and followup. (1985) (1)
- Weight loss (but not weight gain) is a strong predictor of mortality in chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program (2005) (1)
- Comparative effects of Candesartan Cilexetil and Losartan in systemic hypertension (1999) (1)
- Effects of encainide and metabolizer phenotype on ventricular conduction during exercise. (1990) (1)
- Mechanism of ventricular fibrillation of the normal myocardium (1980) (1)
- Non-Canine Animal Models for Evaluating Antiarrhythmic Efficacy (1981) (1)
- The electrocardiogram in valvular heart disease. (1993) (1)
- Comparative effects of stimulus duration on ventricular refractoriness in normal versus chronically infarcted myocardium: Implications for electrophysiologic studies (1982) (1)
- Abstract 844: No Clear Association Between Candidate Gene Variants and Outcomes in 3239 Patients with Chronic Heart Failure: Results from the CHARM Program (2008) (1)
- The diagnosis of arrhythmias: the relative roles of the ECG, Holter monitoring, exercise stress testing, and electrophysiologic studies. (1980) (1)
- Training in clinical cardiology (1995) (1)
- RELATIONSHIP BETWEEN NONSUSTAINED VENTRICULAR TACHYCARDIA AND VASCULAR DEATH IN PATIENTS WITH ACUTE CORONARY SYNDROME IN THE PLATO (PLATELET INHIBITION AND PATIENT OUTCOMES) TRIAL (2012) (1)
- The contributions of ambulatory ECG. (1979) (1)
- Mechanisms sustaining diastolic mitral valve “locking” (1982) (1)
- A049: Effective dose response and tolerability of candesartan cilexetil in isolated systolic hypertension: a clinical experience trial (2000) (1)
- The significance of biphasic R wave amplitude changes during incremental atrial pacing: A sensitive and specific marker for acute myocardial ischemia (1981) (1)
- Can intracardiac volume changes adequately explain R-wave variations associated with acute coronary ischemia? (1980) (1)
- Cardiac Safety Research Consortium (CSRC) (2015) (1)
- Electrophysiology of the sinoatrial and atrioventricular nodes : proceedings of a symposium held during the 60th Annual Scientific Sessions of the American Heart Association in Anaheim, California, November 14, 1987 (1988) (1)
- Critical appraisal of programmed electrical stimulation for evaluating hearts prone to ventricular tachyarrhythmias. (1985) (0)
- Predicting mortality and morbidity in chronic heart failure independent of left ventricular systolic function: Results from the CHARM program (2004) (0)
- Electrophysiology of experimental models of sudden death. (1985) (0)
- Demonstration of heterogeneous extracellular K+ changes at the border zone during acute canine myocardial infarction (1982) (0)
- Guidelines for training in adult cardiovascular medicine: Introduction (1995) (0)
- 408 Incremental benefit of candesartan in heart failure - new analyses of CHARM-Added, according to baseline treatment (2005) (0)
- Abstract 3169: Increase in Risk of Death in Early Months Following Hospitalization for Heart Failure: Observations from the CHARM Program (2006) (0)
- Dissociation of coronary artery ligation arrhythmias and the fractionation of local electrograms (1980) (0)
- Interaction of the input atrial excitatory waves and conduction through the atrioventricular node. I. Changes in the cellular electrical activity. (1985) (0)
- General Group Discussion: Holter Monitoring (1981) (0)
- A038: Comparison of the efficacy and tolerability of candesartan cilexetil and amlodipine in patients with mild systemic hypertension (CASTLE study) (2000) (0)
- Comparative effects of cycle length on ventricular refractoriness of normal and chronically infarcted myocardium (1981) (0)
- Electrophysiological mechanisms of av conduction in response to atrial fibrillation revealed by multiple simultaneous extracellular and intracellular recordings (1981) (0)
- R wave amplitude increase during experimental myocardial ischemia: A predictor for malignant ventricular arrhythmias (1982) (0)
- Public health aspects and optimal systems for ambulatory care. (1988) (0)
- Evidence for central nervous system mediated neural pacemaker modulating arterial pressure oscillations (1990) (0)
- Recognition of mechanical complications of acute myocardial infarction. (1995) (0)
- How to Define Beta-Blocker Usefulness in Hypertension, Angina and Arrhythmias: An Overview (1982) (0)
- Cardiovascular nursing: issues for cardiovascular physician specialists. (1990) (0)
- Women with heart failure are less likely to receive ACE-inhibitors: Findings from the SPICE (Study of patients intolerant of converting enzyme inhibitors) registry (1999) (0)
- Relative Contributions of Mitral and Pulmonary Venous Regurgitation to the Adverse Hemodynamic Consequences of Various Cardiac Arrhythmias (1983) (0)
- Cardiac electrophysiology and pharmacology of adenosine and ATP. Basic and clinical aspects. Proceedings of the 27th annual A.N. Richards Symposium. Bala Cynwyd, Pennsylvania, May 1-2, 1986. (1987) (0)
- Electropharmacology of Diltiazem in a Chronic Canine Myocardial Infarction, Ventricular Tachyarrhythmia Model (1983) (0)
- 594 Differences between diabetic and non‐diabetic patients with chronic heart failure. Baseline demographics from CHARM (2003) (0)
- Elfects of the site and timing of atrioventricular nodal input on atrioventricular conduction in the isolated perfused rabbit heart (2005) (0)
- Spontaneous variability in arrhythmia frequency. (1979) (0)
- Modulation of the effects of postganglionic vagal stimulation in the sinus and atrioventricular nodes by cardioactive agents and electrolytes. (1988) (0)
- Translational analysis of hERG and dog QTc data to man (2014) (0)
- The management of arrhythmias. (1980) (0)
- Mechanisms of sympathetic control of atrioventricular nodal conduction (1990) (0)
- General Group Discussion — How to Define Beta-Blocker Usefulness In: (1982) (0)
- Electrophysiologic studies of the AV conduction system and AV nodal arrhythmias. (1985) (0)
- 640 Total bilirubin and red cell distribution width are powerful independent predictors of outcome in chronic heart failure: results from the CHARM program (2005) (0)
- Body Mass Index and Prognosis in Patients With Chronic Heart Failure Insights From the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program Heart Failure (2007) (0)
- General Group Discussion: Study Designs: Chronic Patients (1981) (0)
- Mean Hourly Ventricular Monitoring Periods Premature Depolarization Frequency for Each of Three 24-Hour Control 3 Day Patient * Age Sex Diagnosis Day 1 Day 2 Day (0)
- Aspirin and perioperative blood loss. (1981) (0)
- Introduction to clinical electrophysiologic studies. (1985) (0)
- The ABC Trial. (2000) (0)
- Title: Analysing recurrent hospitalisations in heart failure: a review of statistical methodology, with application to CHARM-Preserved Short Title: Rogers et al, Analysing recurrent hospitalisations (2015) (0)
- 544 Candesartan improves outcome in patients with low ejection fraction heart failure, irrespective of background dose of ACE inhibitor: a post-hoc analysis of the CHARM-Added trial (2006) (0)
- Implications fortheInterpretation ofElectrophysiolog ic Studies (1981) (0)
- Experimental Reperfusion Ventricular Fibrillation (2005) (0)
- Commentary 2 (2012) (0)
- Effect ofpostganglionic vagalstimulation on the organization ofatrioventricular nodalconduction in isolated rabbit hearttissue (1986) (0)
- Infections and Cardiovascular Disease The Association of Seropositivity to Helicobacter Pylori , Chlamydia Pneumoniae , and Cytomegalovirus With Risk of Cardiovascular Disease A Prospective Study (2016) (0)
- Abstract 3994: Assessment of Heart Failure Therapy Utilization Between Publication of the 2001 and 2005 ACC/AHA Heart Failure Guidelines in a Managed Care Setting (2006) (0)
- Response to Letter Regarding Article, “Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure” (2008) (0)
- Surgical Therapy of Ventricular Tachyarrhythmias: Experimental Models and Cardiac Activation Mapping Techniques (1980) (0)
- RELATIVE CONTRIBUTION OF MITRAL AND PULMONARY VENOUS REGURGITATION TO THE ADVERSE HEMODYNAMIC CONSEQUENCES OF VARIOUS CARDIAC ARRHYTHMIAS : Arrhythmia : 46th Annual Scientific Meeting, Japanese Circulation Society (1982) (0)
- Enalapril plus hydrochlorothiazide versus propranolol plus hydrochlorothiazide in patients with mild to moderate hypertension (1988) (0)
- 588 Differences between younger and older patients with chronic heart failure. Baseline demographics from CHARM (2003) (0)
- RISK OF CARDIOVASCULAR DEATH AND NON-SUSTAINED VENTRICULAR TACHYCARDIA DETECTED 30-DAYS AFTER ACUTE CORONARY SYNDROME IN THE PLATO (PLATELET INHIBITION AND PATIENT OUTCOMES) TRIAL (2014) (0)
- 590 How do men and women with chronic heart failure differ? Baseline demographics from CHARM (2003) (0)
- Man Helping Man: In Memoriam: A Tribute to Leonard S. Dreifus, MD. (2017) (0)
- Increased Vagal Activity (2005) (0)
- Clinical use of sustained-release procainamide in treatment of cardiac arrhythmias. (1988) (0)
- Calcium Entry Blocking Agents: How to Define Controlled Studies in Patients With Arrhythmias (1982) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Eric L. Michelson?
Eric L. Michelson is affiliated with the following schools:
